A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 443 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... December 17, 2021 How we can reduce cancer risk in inflammatory bowel disease patients... August 23, 2022 For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 Load more HOT NEWS Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed...
